Three 4-letter words of hypertension-related cardiac hypertrophy: TRPC, mTOR, and HDAC

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 6, 2011, Pages 964-971

  Kurdi, Mazen ^a,b   Booz, George W ^b  

^a LEBANESE UNIVERSITY   (Lebanon)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac myocyte; Cardiac remodeling; Histone deacetylases; Hypertension; Left ventricular hypertrophy; Mechanosensitive channels

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CHANNEL L TYPE; G PROTEIN COUPLED RECEPTOR; HISTONE DEACETYLASE; MAMMALIAN TARGET OF RAPAMYCIN; MYOCYTE ENHANCER FACTOR 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S6 KINASE; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 4; TRANSIENT RECEPTOR POTENTIAL CHANNEL 5; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6;

AUTOPHAGY; CELL MEMBRANE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; UPREGULATION;

ANIMALS; CARDIOMEGALY; HISTONE DEACETYLASES; HUMANS; HYPERTENSION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRPC CATION CHANNELS;

MAMMALIA;

EID: 79955662616     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.02.004     Document Type: Review

References (91)

1. Booz G.W. Left ventricular physiology in hypertension. Comprehensive hypertension 2007, 113-121. Mosby Elsevier, Philadelphia, PA. Y.H. Lip, J.E. Hall (Eds.).
2. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006, 7:589-600.
3. Berridge M.J., Bootman M.D., Roderick H.L. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 2003, 4:517-529.
4. Molkentin J.D. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 2004, 63:467-475.
5. Watanabe H., Murakami M., Ohba T., Ono K., Ito H. The pathological role of transient receptor potential channels in heart disease. Circ J 2009, 73:419-427.
6. Abramowitz J., Birnbaumer L. Physiology and pathophysiology of canonical transient receptor potential channels. FASEB J 2009, 23:297-328.
7. Sharif-Naeini R., Folgering J.H., Bichet D., Duprat F., Delmas P., Patel A., et al. Sensing pressure in the cardiovascular system: Gq-coupled mechanoreceptors and TRP channels. J Mol Cell Cardiol 2010, 48:83-89.
8. Patel A., Sharif-Naeini R., Folgering J.R., Bichet D., Duprat F., Honoré E. Canonical TRP channels and mechanotransduction: from physiology to disease states. Pflugers Arch 2010, 460:571-581.
9. Ohba T., Watanabe H., Murakami M., Takahashi Y., Iino K., Kuromitsu S., et al. Upregulation of TRPC1 in the development of cardiac hypertrophy. J Mol Cell Cardiol 2007, 42:498-507.
10. Ward M.L., Williams I.A., Chu Y., Cooper P.J., Ju Y.K., Allen D.G. Stretch-activated channels in the heart: contributions to length-dependence and to cardiomyopathy. Prog Biophys Mol Biol 2008, 97:232-249.
11. Seth M., Zhang Z.S., Mao L., Graham V., Burch J., Stiber J., et al. TRPC1 channels are critical for hypertrophic signaling in the heart. Circ Res 2009, 105:1023-1030.
12. 2+ signaling mechanism in cardiac myocytes. Proc Natl Acad Sci USA 2004, 101:16683-16688.
13. Bush E.W., Hood D.B., Papst P.J., Chapo J.A., Minobe W., Bristow M.R., et al. Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J Biol Chem 2006, 281:33487-33496.
14. Wu X., Eder P., Chang B., Molkentin J.D. TRPC channels are necessary mediators of pathologic cardiac hypertrophy. Proc Natl Acad Sci USA 2010, 107:7000-7005.
15. Onohara N., Nishida M., Inoue R., Kobayashi H., Sumimoto H., Sato Y., et al. TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J 2006, 25:5305-5316.
16. Kuwahara K., Wang Y., McAnally J., Richardson J.A., Bassel-Duby R., Hill J.A., et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J Clin Invest 2006, 116:3114-3126.
17. q signaling cascade. Am J Physiol Heart Circ Physiol 2008, 295:H245-H255.
18. Koitabashi N., Aiba T., Hesketh G.G., Rowell J., Zhang M., Takimoto E., et al. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol 2010, 48:713-724.
19. Nishida M., Watanabe K., Sato Y., Nakaya M., Kitajima N., Ide T., et al. Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibition. J Biol Chem 2010, 285:13244-13253.
20. Klaiber M., Kruse M., Völker K., Schröter J., Feil R., Freichel M., et al. Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2. Basic Res Cardiol 2010, 105:583-595.
21. Kinoshita H., Kuwahara K., Nishida M., Jian Z., Rong X., Kiyonaka S., et al. Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-A signaling in the heart. Circ Res 2010, 106:1849-1860.
22. Nishida M., Kurose H. Roles of TRP channels in the development of cardiac hypertrophy. Naunyn Schmiedebergs Arch Pharmacol 2008, 378:395-406.
23. 2/ω-hydroxylase/20-HETE pathways. Circ Res 2009, 104:1399-1409.
24. Keshava Prasad T.S., Goel R., Kandasamy K., Keerthikumar S., Kumar S., Mathivanan S., et al. Human Protein Reference Database-2009 update. Nucleic Acids Res 2009, 37(Database issue):D767-72.
25. Booz G.W. Putting the brakes on cardiac hypertrophy: exploiting the NO-cGMP counter-regulatory system. Hypertension 2005, 45:341-346.
26. Fiedler B., Lohmann S.M., Smolenski A., Linnemuller S., Pieske B., Schroder F., et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci USA 2002, 99:11363-11368.
27. 2+ channel. Circ Res 2009, 105:51-60.
28. 3 receptor regulates cardiac hypertrophy in response to select stimuli. Circ Res 2010, 107:659-666.
29. van Oort R.J., Respress J.L., Li N., Reynolds C., De Almeida A.C., Skapura D.G., et al. Accelerated development of pressure overload-induced cardiac hypertrophy and dysfunction in an RyR2-R176Q knockin mouse model. Hypertension 2010, 55:932-938.
30. Frank D., Frauen R., Hanselmann C., Kuhn C., Will R., Gantenberg J., et al. Lmcd1/Dyxin, a novel Z-disc associated LIM protein, mediates cardiac hypertrophy in vitro and in vivo. J Mol Cell Cardiol 2010, 49:673-682.
31. Bian Z.Y., Huang H., Jiang H., Shen D.F., Yan L., Zhu L.H., et al. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling. Hypertension 2010, 55:257-263.
32. Tokudome T., Kishimoto I., Horio T., Arai Y., Schwenke D.O., Hino J., et al. Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation 2008, 117:2329-2339.
33. Takimoto E., Koitabashi N., Hsu S., Ketner E.A., Zhang M., Nagayama T., et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest 2009, 119:408-420.
34. Balasubramanian S., Johnston R.K., Moschella P.C., Mani S.K., Tuxworth W.J., Kuppuswamy D. mTOR in growth and protection of hypertrophying myocardium. Cardiovasc Hematol Agents Med Chem 2009, 7:52-63.
35. Gurusamy N., Lekli I., Mukherjee S., Ray D., Ahsan M.K., Gherghiceanu M., Popescu L.M., Das D.K. Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc Res 2010, 86:103-112.
36. Jung C.H., Ro S.H., Cao J., Otto N.M., Kim D.H. mTOR regulation of autophagy. FEBS Lett 2010, 584:1287-1295.
37. Ganley I.G., Lam du H., Wang J., Ding X., Chen S., Jiang X. ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. J Biol Chem 2009, 284:12297-12305.
38. Zhang D., Contu R., Latronico M.V., Zhang J., Rizzi R., Catalucci D., Miyamoto S., Huang K., Ceci M., Gu Y., Dalton N.D., Peterson K.L., Guan K.L., Brown J.H., Chen J., Sonenberg N., Condorelli G. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J Clin Invest 2010, 120:2805-2816.
39. Umar S., van der Valk E.J., Schalij M.J., van der Wall E.E., Atsma D.E., van der Laarse A. Integrin stimulation-induced hypertrophy in neonatal rat cardiomyocytes is NO-dependent. Mol Cell Biochem 2009, 320:75-84.
40. Shioi T., McMullen J.R., Tarnavski O., Converso K., Sherwood M.C., Manning W.J., et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003, 107:1664-1670.
41. 3 integrin in adult cardiac muscle cells. J Biol Chem 2003, 278:42214-42224.
42. δ, in adult cardiac muscle cells. J Mol Cell Cardiol 2007, 43:754-766.
43. Soesanto W., Lin H.Y., Hu E., Lefler S., Litwin S.E., Sena S., et al. Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 2009, 54:1321-1327.
44. Booz G.W., Baker K.M. Protein phosphorylation. Hypertension primer: the essentials of high blood pressure 2008, 16-21. Lippincott Williams & Wilkins, Baltimore, Maryland. 4th ed. J.L. Izzo, H.R. Black (Eds.).
45. Huang B.P., Wang Y., Wang X., Wang Z., Proud C.G. Blocking eukaryotic initiation factor 4F complex formation does not inhibit the mTORC1-dependent activation of protein synthesis in cardiomyocytes. Am J Physiol Heart Circ Physiol 2009, 296:H505-H514.
46. Dowling R.J., Topisirovic I., Alain T., Bidinosti M., Fonseca B.D., Petroulakis E., et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 2010, 328:1172-1176.
47. Cheng Y., Li H., Ren X., Niu T., Hait W.N., Yang J. Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition. PLoS ONE 2010, 5:e9715.
48. Kantidakis T., Ramsbottom B.A., Birch J.L., Dowding S.N., White R.J. mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1. Proc Natl Acad Sci USA 2010, 107:11823-11828.
49. Xu X., Fassett J., Hu X., Zhu G., Lu Z., Li Y., et al. Ecto-5'-nucleotidase deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction. Hypertension 2008, 51:1557-1564.
50. Li H.L., Yin R., Chen D., Liu D., Wang D., Yang Q., et al. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy. J Cell Biochem 2007, 100:1086-1099.
51. Zhang P., Hu X., Xu X., Fassett J., Zhu G., Viollet B., et al. AMP activated protein kinase-α2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 2008, 52:918-924.
52. Wong A.K., Howie J., Petrie J.R., Lang C.C. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin Sci (Lond) 2009, 116:607-620.
53. Kim A.S., Miller E.J., Young L.H. AMP-activated protein kinase: a core signalling pathway in the heart. Acta Physiol (Oxf) 2009, 196:37-53.
54. MacDonnell S.M., Weisser-Thomas J., Kubo H., Hanscome M., Liu Q., Jaleel N., et al. CaMKII negatively regulates calcineurin-NFAT signaling in cardiac myocytes. Circ Res 2009, 105:316-325.
55. Ikeda Y., Sato K., Pimentel D.R., Sam F., Shaw R.J., Dyck J.R., et al. Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. J Biol Chem 2009, 284:35839-35849.
56. Shimano M., Ouchi N., Shibata R., Ohashi K., Pimentel D.R., Murohara T., et al. Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J Mol Cell Cardiol 2010, 49:210-220.
57. Dolinsky V.W., Chan A.Y., Robillard Frayne I., Light P.E., Des Rosiers C., Dyck J.R. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009, 119:1643-1652.
58. Pillai V.B., Sundaresan N.R., Kim G., Gupta M., Rajamohan S.B., Pillai J.B., et al. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J Biol Chem 2010, 28:3133-3144.
59. + depletion and reduced Sir2α deacetylase activity. J Biol Chem 2005, 280:43121-43130.
60. Marin T.M., Clemente C.F., Santos A.M., Picardi P.K., Pascoal V.D., Lopes-Cendes I., et al. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways. Circ Res 2008, 103:813-824.
61. Bush E.W., McKinsey T.A. Targeting histone deacetylases for heart failure. Expert Opin Ther Targets 2009, 13:767-784.
62. Verdin E., Dequiedt F., Kasler H.G. Class II histone deacetylases: versatile regulators. Trends Genet 2003, 19:286-293.
63. Oka S., Ago T., Kitazono T., Zablocki D., Sadoshima J. The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy. J Mol Med 2009, 87:785-791.
64. Martini J.S., Raake P., Vinge L.E., DeGeorge B.R., Chuprun J.K., Harris D.M., et al. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci USA 2008, 105:12457-12462.
65. Backs J., Backs T., Neef S., Kreusser M.M., Lehmann L.H., Patrick D.M., et al. The δ isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci USA 2009, 106:2342-2347.
66. Little G.H., Bai Y., Williams T., Poizat C. Nuclear calcium/calmodulin-dependent protein kinase IIδ preferentially transmits signals to histone deacetylase 4 in cardiac cells. J Biol Chem 2007, 282:7219-7231.
67. 2+ signaling in cardiac myocyte excitation-transcription coupling. J Clin Invest 2006, 116:675-682.
68. Monovich L., Vega R.B., Meredith E., Miranda K., Rao C., Capparelli M., et al. A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase. FEBS Lett 2010, 584:631-637.
69. Monovich L., Koch K.A., Burgis R., Osimboni E., Mann T., Wall D., et al. Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1. Biochim Biophys Acta 2009, 1789:422-431.
70. Bush E.W., McKinsey T.A. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ Res 2010, 106:272-284.
71. Kong Y., Tannous P., Lu G., Berenji K., Rothermel B.A., Olson E.N., et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006, 113:2579-2588.
72. Kee H.J., Kook H. Krüppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy. J Mol Cell Cardiol 2009, 47:770-780.
73. Trivedi C.M., Luo Y., Yin Z., Zhang M., Zhu W., Wang T., et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007, 13:324-331.
74. Kee H.J., Eom G.H., Joung H., Shin S., Kim J.R., Cho Y.K., et al. Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy. Circ Res 2008, 103:1259-1269.
75. Riccio A. New endogenous regulators of class I histone deacetylases. Sci Signal 2010, pe1.
76. Karliner J.S. Lysophospholipids and the cardiovascular system. Biochim Biophys Acta 2002, 1582:216-221.
77. Glenn D.J., Wang F., Chen S., Nishimoto M., Gardner D.G. Endothelin-stimulated human B-type natriuretic peptide gene expression is mediated by Yin Yang 1 in association with histone deacetylase 2. Hypertension 2009, 53:549-555.
78. Oudit G.Y., Penninger J.M. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res 2009, 82:250-260.
79. Kwon Y., Hofmann T., Montell C. Integration of phosphoinositide- and calmodulin-mediated regulation of TRPC6. Mol Cell 2007, 25:491-503.
80. Saleh S.N., Albert A.P., Large W.A. Activation of native TRPC1/C5/C6 channels by endothelin-1 is mediated by both PIP3 and PIP2 in rabbit coronary artery myocytes. J Physiol 2009, 587:5361-5375.
81. Kee H.J., Kook H. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy. J Biomed Biotechnol 2011, 2011:928326.
82. Zhu W., Trivedi C.M., Zhou D., Yuan L., Lu M.M., Epstein J.A. Inpp 5f is a polyphosphoinositide phosphatase that regulates cardiac hypertrophic responsiveness. Circ Res 2009, 105:1240-1247.
83. Sabourin J., Cognard C., Constantin B. Regulation by scaffolding proteins of canonical transient receptor potential channels in striated muscle. J Muscle Res Cell Motil 2009, 30:289-297.
84. Pouliquin P., Dulhunty A.F. Homer and the ryanodine receptor. Eur Biophys J 2009, 39:91-102.
85. Stiber J.A., Tabatabaei N., Hawkins A.F., Hawke T., Worley P.F., Williams R.S., Rosenberg P. Homer modulates NFAT-dependent signaling during muscle differentiation. Dev Biol 2005, 287:213-224.
86. Vollenbröker B., George B., Wolfgart M., Saleem M.A., Pavenstädt H., Weide T. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Ren Physiol 2009, 296:F418-F426.
87. Artham S.M., Lavie C.J., Milani R.V., Patel D.A., Verma A., Ventura H.O. Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis 2009, 52:153-167.
88. Koren M.J., Ulin R.J., Koren A.T., Laragh J.H., Devereux R.B. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 2002, 15:1021-1028.
89. Mancia G., Carugo S., Grassi G., Lanzarotti A., Schiavina R., Cesana G., et al. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Hypertension 2002, 39:744-749.
90. Brown D.W., Giles W.H., Croft J.B. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000, 140:848-856.
91. Dong D.L., Chen C., Huo R., Wang N., Li Z., Tu Y.J., et al. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy. Hypertension 2010, 55:946-952.